-
1 Comment
Haisco Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 9.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
Haisco Pharmaceutical Group Co., Ltd's total revenue rose by 0.4% to $954M since the same quarter in the previous year.
Its net income has increased by 111.3% to $234M since the same quarter in the previous year.
Finally, its free cash flow fell by 119.2% to $-21M since the same quarter in the previous year.
Based on the above factors, Haisco Pharmaceutical Group Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100001BC7 |
| Sector | Healthcare |
| Beta | -0.09 |
|---|---|
| Market Cap | 48B |
| PE Ratio | 138.68 |
| Target Price | 59.54 |
| Dividend Yield | 1.4% |
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals products in China. The company offers anesthetic analgesic, neuropsychiatric system, digestive liver disease, and parenteral nutrition medications; drugs for endocrine system and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anaesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation during mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offer its products for anesthesia; analgesia; and chronic metabolic, respiratory, and autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002653.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
